Trial
NCT00754052
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Eisai Inc.
Collaborators
Pfizer
Condition
Down Syndrome
Intervention
Aricept (donepezil hydrochloride)
Why stopped
Sufficient evidence of efficacy not met. Discontinuation not based on any safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-04-23